The development of small molecule antivirals that target viral RNA in Henipaviruses will benefit from a $1.7million grant from Open Philanthropy, a philanthropic funder prioritizing global health and wellbeing.
Skyhawk enters an agreement with Merck to discover and develop small molecules to modulate RNA splicing, and expands its existing development agreement with Biogen.
Novartis exercises its option to license Ionis’ RNA-targeting cardiovascular drug, adding to its cardiovascular treatment portfolio, as Entresto reaches the three-year mark on its patent.
Scipher announced positive outcomes of its retrospective trial for its test Prism used to predict clinical utility, with data predicting it could double patients’ response rate to major therapies.
VGXI, a subsidiary of GeneOne, signed a licensing agreement with Houston Methodist Research Institute to produce RNA one of the most valued clinical ingredients.
Alexion Pharmaceuticals will use the LNP delivery licensed from Arbutus Biopharma as part of its messenger RNA therapeutics development partnership with Moderna Therapeutics.
Alnylam’s RNAi manufacturing plant will be operational by 2018 and the firm says it is willing to invest in a second facility depending on its pipeline success.
Roche has renewed its interest in gene silencing drugs, paying $250m (€187m) for Santaris Pharma including its ‘antisense’ Locked Nucleic Acid (LNA) platform.
Bayer has inked a deal with preclinical CRO Cenix BioScience to use its genome-scale RNA interference (RNAi) platform to target an undisclosed disease.
RNA interference (RNAi) developers that saw stock prices fall after Novartis pulled out of the market last week have reiterated their belief in the therapeutic and revenue potential of gene silencing drugs.
New research could make it possible for scientists to use silicon particles as an effective drug delivery system that enables fragile small interfering RNA (siRNA) based drugs to be directly transported to the disease’s location.
MDRNA’s liposomal drug delivery formulation, DiLA2, lost no potency when stored for 12 months in conditions ranging from -80ºC to 4ºC, helping to validate it for administration of UsiRNA.
US RNA interference (RNAi) specialist MDRNA has signed a non-exclusive licensing deal granting Swiss drug giant Novartis access to its liposomal siRNA delivery technology platform.
Abbott Laboratories has licensed Liquidia Technologies’ PRINT nanoparticle technology for the delivery of siRNA-based therapeutics, which have the potential to improve the company’s cancer portfolio.
Novartis’ extension of its collaboration with Alnylam Therapeutics and Roche’s acquisition of gene silencing specialist Mirus Bio Corp for $125m (€78.5m) suggest that big pharma is beginning to recognize the commercial potential of RNAi-based therapeutics.
Bio-Rad has launched a new web-based search tool to give researchers easier access to its validated siLentMer gene silencing product line, which offers up to twice the silencing longevity.
An artificial self-assembling virus capable of serving as a drug
delivery system has been created by researchers in Korea, according
to a publication in Angewandte Chemie.
Agilent Technologies is expanding its nucleic acid active
pharmaceutical ingredient (API) manufacturing facility in Boulder,
Colorado, US, as the industry gravitates towards the
development of oligonucleotide-based drugs.
Febit has updated its Geniom microRNA analysis platform with the
latest version of the Sanger Institute's database of all known
miRNA elements. The upgrade should provide scientists with a more
detailed microRNA profile of their...
Research into the use of RNA interference (RNAi) to "silence" gene
activity has taken another step forwards, saysThermo Fisher
Scientific which has launched an agent that accelerates the
processes in which RNAi is used to...
Illumina has released a new microRNA (miRNA) assay for gene
expression profiling at a cost that the company believes is less
than half that of other commercially available systems.
Drug developers have a new target to aim at in the fight against
obesity after the discovery that a certain protein in the body
stimulates the formation of fat cells.
Applied Biosystems (ABI) has launched its TaqMan microRNA (miRNA)
assays in array format to help researchers search for miRNA
biomarkers more efficiently from smaller samples.
Integrated DNA Technologies (IDT) has launched a new kit for
cloning libraries of small RNAs from any primary RNA source to
enable the discovery of new small RNA molecules.
An unusual drug that contains a crucial boron atom can effectively
treat fungal infections, and could also prove invaluable in the
effort to counter antibacterial drug resistance.
US researchers have developed a novel delivery vehicle for siRNA,
an up-and-coming technology for switching off genes in the body
that could accelerate its use in drug development.
Alnylam has been issued a US patent, which protects its method of
making small interfering RNAs with and without chemical
modifications, which is set to have far reaching implications in
future drug discovery.
SR Pharma has recruited Genzyme, BioSpring and OctoPlus to
formulate and manufacture its lead RNAi therapeutic product Atu027
to good manufacturing practice (GMP) standards, as its liposomal
drug delivry system moves forward.
Biotechnology firm SR Pharma has announced a technical breakthrough
in the formulation of siRNA drugs, enabling them to be stored at
room temperature and reconstituted in one simple step, thus
extending shelf life and making administration...
